Still unanswered questions about the Oxford COVID-19 vaccine

The cloud hanging over the Oxford COVID-19 vaccine has not lifted despite today’s publication in the Lancet of the results from the Phase 3 trial, which concluded that overall the trial participants got 70 % protection against infection (compared to those who got the placebo).

What cloud?

Why the vaccine seemed to work significantly better when given in a half-dose (followed by a full dose) as opposed to when given in 2 full doses.

And since there was nobody under age 55 in that half-dose group, how well will this vaccine work in seniors?

Before this vaccine goes full Monty, it’s imperative that these questions get settled.